Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2006 1
2007 1
2009 2
2010 1
2011 1
2015 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of GSK2795039, a Novel Small Molecule NADPH Oxidase 2 Inhibitor.
Hirano K, Chen WS, Chueng AL, Dunne AA, Seredenina T, Filippova A, Ramachandran S, Bridges A, Chaudry L, Pettman G, Allan C, Duncan S, Lee KC, Lim J, Ma MT, Ong AB, Ye NY, Nasir S, Mulyanidewi S, Aw CC, Oon PP, Liao S, Li D, Johns DG, Miller ND, Davies CH, Browne ER, Matsuoka Y, Chen DW, Jaquet V, Rutter AR. Hirano K, et al. Among authors: ong ab. Antioxid Redox Signal. 2015 Aug 10;23(5):358-74. doi: 10.1089/ars.2014.6202. Antioxid Redox Signal. 2015. PMID: 26135714 Free PMC article.
Cognitive enhancing effects of ghrelin receptor agonists.
Atcha Z, Chen WS, Ong AB, Wong FK, Neo A, Browne ER, Witherington J, Pemberton DJ. Atcha Z, et al. Among authors: ong ab. Psychopharmacology (Berl). 2009 Oct;206(3):415-27. doi: 10.1007/s00213-009-1620-6. Epub 2009 Aug 4. Psychopharmacology (Berl). 2009. PMID: 19652956
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.
Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, Camitta BM, Raimondi SC, Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Lim R, Lim HL, Ong AB, Lee HS, Kuehl P, Zhang J, Lin Y, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS. Schuetz EG, et al. Among authors: ong ab. Pharmacol Rev. 2004 Jun;56(2):159. doi: 10.1124/pr.56.2.1. Pharmacol Rev. 2004. PMID: 15169924 No abstract available.
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh BC. Wong CI, et al. Among authors: ong ab. J Clin Oncol. 2009 Oct 1;27(28):4718-26. doi: 10.1200/JCO.2008.21.7125. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720910 Clinical Trial.